CRISPR Therapeutics Announces Leadership Transition
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September…
ISP
CRISPR Therapeutics Announces Leadership Transition
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September…
iSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive Profitability
Company to Focus on Core Revenue Drivers, New Revenue Growth Opportunities from Recently Launched Sequencing…
Editas Medicine Announces Upcoming Investor Events
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage…
Editas Medicine Announces Upcoming Investor Events
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage…
Ubiquiti Inc. Reports Fourth Quarter Fiscal 2023 Financial Results
~ Revenues of $491.1 million ~ ~ GAAP Diluted Earnings Per Share of $1.72 ~…
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
Designed to demonstrate delivery of TTX-MC138 to metastatic lesions BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE)…
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
Designed to demonstrate delivery of TTX-MC138 to metastatic lesions BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE)…
Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1
Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primates…
Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1
Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primates…
iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers
New Capabilities Enable Platform to Efficiently Collect and Store Most Up-to-Date Data from Providers and…
iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers
New Capabilities Enable Platform to Efficiently Collect and Store Most Up-to-Date Data from Providers and…
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion…
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion…
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
-FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease…
Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Arbor Biotechnologies®, a biotechnology company discovering and…
Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Arbor Biotechnologies®, a biotechnology company discovering and…
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for…